Cargando…
Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
By analogy with combination chemotherapy, endocrine agents with different mechanisms of action have been combined in the treatment of patients with advanced breast cancer. The clinical use of tamoxifen+aminoglutethimide+hydrocortisone showed no clinical benefit over the individual use of tamoxifen o...
Autores principales: | Dowsett, M., Harris, A. L., Smith, I. E., Jeffcoate, S. L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1984
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976801/ https://www.ncbi.nlm.nih.gov/pubmed/6540595 |
Ejemplares similares
-
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983) -
Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
por: Harris, A. L., et al.
Publicado: (1983) -
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985) -
Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1985) -
Role of aminoglutethimide in male breast cancer.
por: Harris, A. L., et al.
Publicado: (1986)